Effect of resveratrol on treatment of bleomycin-Induced pulmonary fibrosis in rats

Inflammation

Volumn 35, Issue 5, 2012, Pages 1732-1741

  Akgedik, Recep ^a   Akgedik, Sükran ^a   Karamanli, Harun ^b   Uysal, Sema ^c   Bozkurt, Bülent ^c   Ozol, Duygu ^c   Armutcu, Ferah ^c   Yildirim, Zeki ^c  

^a Ordu State Hospital   (Turkey)

^b Yozgat State Hospital   (Turkey)

^c FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

Author keywords

Bleomycin; Hydroxyproline; Idiopathic pulmonary fibrosis; Lung fibrosis; Oxidative stress; Resveratrol treatment

Indexed keywords

BLEOMYCIN; HYDROXYPROLINE; MALONALDEHYDE; RESVERATROL; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; LUNG FIBROSIS; LUNG LAVAGE; MALE; METABOLIC PARAMETERS; NONHUMAN; OXIDATIVE STRESS; RAT; SCORING SYSTEM; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TISSUE LEVEL; TOTAL ANTIOXIDANT CAPACITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; HYDROXYPROLINE; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PULMONARY FIBROSIS; RANDOM ALLOCATION; RATS; RATS, WISTAR; STILBENES;

RATTUS;

EID: 84866737130     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9491-0     Document Type: Article

References (34)

1. Noth, I., and F.J. Martinez. 2007. Recent advances in idiopathic pulmonary fibrosis. Chest 132: 637-650.
2. Idiopathic Pulmonary Fibrosis. 2000. Diagnosis and treatment (International Consensus Statement). American Journal of Respiratory and Critical Care Medicine 161: 646-664.
3. Walters, D.M., H.Y. Cho, and S.R. Kleeberger. 2008. Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: A potential role for Nrf2. Antioxidants & Redox Signaling 10: 321-332.
4. Chaudhary, N.I., A. Schnapp, and J.E. Park. 2006. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. American Journal of Respiratory and Critical Care Medicine 173: 769-776.
5. Moeller, A., K. Ask, D. Warburton, J. Gauldie, and M. Kolb. 2008. The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? The International Journal of Biochemistry & Cell Biology 40: 362-382.
6. Yildirim, Z.,M. Kotuk,M. Iraz, I. Kuku, R. Ulu, F. Armutcu, and S. Ozen. 2005. Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats: Erdosteine and N-acetylcysteine. Pulmonary Pharmacology and Therapeutic 18: 367-373.
7. Sogut, S., H. Ozyurt, F. Armutcu, L. Kart, M. Iraz, O. Akyol, S. Ozen, S. Kaplan, I. Temel, and Z. Yildirim. 2004. Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats. European Journal of Pharmacology 494: 213-220.
8. Yildirim, Z., Y. Turkoz, M. Kotuk, F. Armutcu, A. Gurel, M. Iraz, S. Ozen, I. Aydogdu, and O. Akyol. 2004. Effects of aminoguanidine and antioxidant erdosteine on bleomycin-induced lung fibrosis in rats. Nitric Oxide 11: 156-165.
9. Ozyurt, H., S. Sogut, Z. Yildirim, L. Kart, M. Iraz, F. Armutçu, I. Temel, S. Ozen, A. Uzun, and O. Akyol. 2004. Inhibitory effect of caffeic acid phenethyl ester (cape) on bleomycine-induced lung fibrosis in rats. Clinica Chimica Acta 339: 65-75.
10. Yildirim, Z., M. Kotuk, H. Erdogan, M. Iraz, M. Yagmurca, I. Kuku, and E. Fadillioglu. 2006. Preventive effect of melatonin on bleomycin-induced lung fibrosis in rats. Journal of Pineal Research 40: 27-33.
11. Iraz, M., H. Erdogan, M. Kotuk, M. Yagmurca, T. Kilic, H. Ermis, E. Fadillioglu, and Z. Yildirim. 2006. Ginkgo biloba inhibits bleomycin-induced lung fibrosis in rats. Pharmacological Research 53: 310-316.
12. Sener, G., N. Topaloǧlu, A.O. Sehirli, F. Ercan, and N. Gedik. 2007. Resveratrol alleviates bleomycin-induced lung injury in rats. Pulmonary Pharmacology & Therapeutics 20: 642-649.
13. Signorelli, P., and R. Ghidoni. 2005. Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises. The Journal of Nutritional Biochemistry 16: 449-466.
14. Li, Y., Z. Cao, and H. Zhu. 2006. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stres. Pharmacological Research 53: 6-15.
15. Wenzel, E., and S.V. Germany. 2005. Metabolism and bioavailability of trans-resveratrol. Molecular Nutrition & Food Research 49: 472-481.
16. De La Lastra, C.A., and I. Villegas. 2007. Resveratrol as an antioxidant and pro-oxidant agent: Mechanisms and clinical implications. Biochemical Society Transactions 35: 1156-1160.
17. Wood, L.G., P.A. Wark, and M.L. Garg. 2010. Antioxidant and antiinflammatory effects of resveratrol in airway disease. Antioxidants & Redox Signaling 13: 1535-1548.
18. Bradamante, S., L. Barenghi, and A. Villa. 2004. Cardiovascular protective effects of resveratrol. Cardiovascular Drug Reviews 22: 169-188.
19. Serrano-Mollar, A., D. Closa, N. Prats, S. Blesa, M. Martinez-Losa, J. Cortijo, J.M. Estrela, E.J. Morcillo, and O. Bulbena. 2003. In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats. British Journal of Pharmacology 138: 1037-1048.
20. Ashcroft, T., J.M. Simpson, and V. Timbrell. 1988. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. Journal of Clinical Pathology 41: 467-470.
21. Draper, H.H., and M. Hadley. 1990. A review of recent studies on the metabolism of exogenous and endogenous malondialdehyde. Xenobiotica 20: 901-907.
22. Woessner, J.B. 1961. The determination of hidroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophysics 93: 440-447.
23. Erel, O. 2004. A novel automated method to measure total antioxidant response against potent free radical reactions. Clinical Biochemistry 37: 112-119.
24. Aoki, F., M. Kurabayashi, Y. Hasegawa, and I. Kojima. 2005. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. American Journal of Respiratory and Critical Care Medicine 172: 713-720.
25. Kakugawa, T., H. Mukae, T. Hayashi, H. Ishii, K. Abe, T. Fujii, et al. 2004. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. European Respiratory Journal 24: 57-65.
26. Piguet, P.F., and C. Vesin. 1994. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. European Respiratory Journal 7: 515-518.
27. Piguet, P.F., C. Vesin, G.E. Grau, and R.C. Thompson. 1993. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 5: 57-61.
28. Piguet, P.F., H. Rosen, C. Vesin, and G.E. Grau. 1993. Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD-11 antibodies. American Review of Respiratory Disease 147: 435-441.
29. Olson, E.R., J.E. Naugle, X. Zhang, J.A. Bomser, and J.G. Meszaros. 2005. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. American Journal of Physiology-Heart and Circulatory Physiology 288: 1131-1138.
30. Wang, Z.P., Y.M. Hua, X. Zhang, Y.B. Wang, X.Q. Shi, and M.Y. Li. 2009. Effect of resveratrol on myocardial fibrosis in mice withchronic viral myocarditis. Zhongguo Dang Dai Er Ke Za Zhi 11: 291-295.
31. Fagone, E., E. Conte, E. Gili, M. Fruciano, M.P. Pistorio, D. Lo Furno, R. Giuffrida, N. Crimi, and C. Vancheri. 2011. Resveratrol inhibits transforming growth factor-β-induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through ERK/Akt inhibition and PTEN restoration. Experimental Lung Research 37: 162-174.
32. Athar, M., J.H. Back, L. Kopelovich, D.R. Bickers, and A.L. Kim. 2009. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Archives of Biochemistry and Biophysics 15(486): 95-102.
33. Edwards, J.A., M. Beck, C. Riegger, and J. Bausch. 2011. Safety of resveratrol with examples for high purity, trans-resveratrol, resVida(®). Annals of the New York Academy of Sciences 1215: 131-137.
34. Williams, L.D., G.A. Burdock, J.A. Edwards, M. Beck, and J. Bausch. 2009. Safety studies conducted on high-purity transresveratrol in experimental animals. Food and Chemical Toxicology 47: 2170-2182.